Pharmacokinetics of all-trans retinoic acid (ATRA) in patients with renal cancer concomitantly treated with interferon alpha 2A (IFN)

International Journal of Pharmaceutics

Volumn 134, Issue 1-2, 1996, Pages 99-104

  Bonhomme Faivre, L ^a   Paule, B ^a   Urien, S ^b   Rudant, E ^a   Bottius, L ^a   Pradel, D ^a   Marrot, D ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b FACULTÉ DE MÉDECINE   (France)

Author keywords

All trans retinoic acid; HPLC assay; Interferon alpha 2a; Pharmacokinetics; Renal cell cancer

Indexed keywords

ALPHA2A INTERFERON; RETINOIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CANCER; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030060998     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(95)04452-3     Document Type: Article

References (20)

1. Adamson, P.C., Balis, F.M., Yarchoan, R., Pluda, J.M., Bailey, J., Murphy, R.F., Bauza, S. and Poplack, D.G., Pharmacokinetics of all trans retinoic acid administered on an intermittent schedule. Proceeding 84 th annual meeting of the American Association for Cancer Research, (1993) May 19-22 Orlando, 34, (no. 1265) p. 212.
2. Bonhomme, L., Fredj, G., Ecstein, E., Maurisson, G., Farabos, C., Misset, J.L. and Jasmin, C., Systemic treatment of AIDS Associated Kaposi's Sarcoma with all trans retinoic acid. Am. J. Hosp. Pharm., 51 (1994) 2417-2419.
3. Chiang, T.C. Gas chromatographic and spectrometric assay for low levels of retinoic acid in human blood. J Chromatog., 192 (1980) 335-340.
4. Chomienne, C., Ballerini, P., Balitrand, N., Amar, M., Bernard, J.F., Boivin, P., Daniel M.T., Berger, R., Castaigne, S. and Degos, L., Retinoic acid therapy for promyelocytic leukemia. Lancet, 8665 (1989) 746-747.
5. Cribb, A.E. and Renton, K.W., Dissociation of xanthine oxidase induction and cytochrome P450 depression during interferon induction in the rat. Biochem. Pharmacol., 3, 46 (1993) 2114-2117.
6. De Ruyter, M.G., Lambert, W.E. and De Leenheer, A.P., Retinoic acid: an endogenous compound of human blood. Unequivocal demonstration of endogenous retinoic acid in normal physiological conditions. Anal. Biochem., 98 (1979) 402-409.
7. El Mansouri, S., Tod, M., Leclercq, M., Petitjean, O., Perret G. and Porthault, M., Time and dose-dependant Kinetics of all trans retinoic acid in rats after oral or intravenous administrations. Drugs Metab. Disposit., 23, 2 (1995) 227-231.
8. Guiso, G., Rambaldi, A., Dimitrova, B., Biondi and Caccia, S., Determination of orally administered all-trans retinoic acid in human plasma by high performance liquid chromatography. J Chromatog. B. 656 (1994) 239-244.
9. Iakuwa, T., Hirotani, K. and Nakamura, O., A highly potent antiangiogenic activity of retinoids. Cancer Lett, 48, 2, (1989) 157-162.
10. Lefebvre, P., Thomas, G., Gourmel, B., Agadir, A., Castaigne, S., Dreux, C., Degos, L. and Chonienne, C., Pharmacokinetics of oral all trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia, 5, 12 (1991) 1054-1058.
11. Lucek, R.W. and Colburn, W.A., Clinical pharmacokinetics of the retinoids. Clini Pharmacokinet., 10, 1 (1985) 38-62.
12. Mannering, G.J., Deloria, L.B. and Abbott, V., Rôle of xanthine oxidase in the interferon mediated depression of the hepatic cytochrome P-450 system in mice. Cancer Res., 48, 8 (1988) 2107-2112.
13. Muindi, J., Frankel, S.R., Huselton C., De Grazia, F., Garland, W.A., Young, C. and Warrell, R.P., Clinical pharmacology of oral all trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res., 52, 2 (1992) 138-142.
14. Muindi, J. and Young, C., catabolism of all trans retinoic acid by human cell microsomes selectively enriched in specified cytochrome P450 enzymes. Abstract: 5 th International Congress on differentiation Therapy. Biomedecine and Pharmacotherapy. Villasimus Sardenia, (1992) September 2-5, 46, 5/6/7, no. 98, p. 287.
15. Namus, D.M., Bogenrieder, T., Engelstein, Bentel, J.M., Miller, W. M. and Albino, A.P., Analysis of retinoid receptors (RAR) and retinoid induced antiproliferative effects alone and in combination with interferon a in human renal cancers: aberrant RAR a transcript in a retinoid resistant cell line. 85th Annual meeting of the AACR San Francisco. (1994) April 10-3, vol 35, no. 506, p. 85.
16. ème forum de cancerologie (abstract) Bull. Cancer, 82, 6, (1995) 014.
17. Pilot, H.C., Rubin, J., Burch, P.B., Svingen, P.A. and Kovach, J.S., Phase I study of all trans retinoic acid (5NSC 122758) in solid tumors on an intermittent schedule. Proceedings 85th annual meeting of the American Association for cancer research, (1994) vol 35, no. 1462, p. 245.
18. Rigas, J.R., Francis, P.A., Muindi, J.R., Kris, M.G., Muselton, C., De-Grazia, F., Orazen, J.P., Young, C.W. and Warrell, R.P., Constitutive variability in the pharmacokinetics of the natural retinoid, all trans retinoic acid, and its modulation by ketoconazole. J. Natl. Cancer Inst., 85, 23 (1993) 1921-1926.
19. Smith, M.A., Adamson, P.C., Balis, F.M., Feusner, J., Aronson, L., Murphy, R.F., Morowitz, M.E., Reaman, G., Demann, H., Fenton, R.M., Connaghan, G.D., Hittelman, W.N. and Poplack, D.G., Phase I and pharmacokinetic evaluation of all trans retinoic acid in pediatric patients with cancer. J Clinical Oncol., 10, 11 (1992) 1666-1673.
20. Smith, D.C., Jacobs, M.E. and Lotze, M.T., A phase I trial of interferon a 2A (INF a) and all trans retinoic acid (ATRA): a pharmacokinetic assessment. 30th Annual meeting of the American Society of Clinical Oncology, (1994) May 14-17, Dallas vol 134, no. 329.